C4 Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report. C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders using its TORPEDO platform; it had no product sales or approved products.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Collaboration revenue | $31.1 million | $45.8 million |
| Research and development expense | $117.8 million | $94.7 million |
| General and administrative expense | $42.8 million | $33.3 million |
| Operating loss | $129.5 million | $82.1 million |
| Net loss | $128.2 million | $83.9 million |
| Net loss per share, basic and diluted | $2.62 | $1.82 |
| Net cash used in operating activities | $105.9 million | $87.0 million |
- Revenue came from Roche ($4.9 million), Biogen ($19.2 million), and Calico ($6.9 million). No collaboration royalties had been received.
- At year-end, cash and cash equivalents were $29.8 million and marketable securities were $307.4 million, totaling approximately $337.1 million in cash, cash equivalents, and marketable securities. The filing reports $33.0 million in cash, cash equivalents, and restricted cash.
- Long-term debt had $12.5 million principal outstanding, secured by substantially all assets; the stated interest rate was 13.63% at year-end. Principal payments began in 2023, with maturity in June 2024.
- Operating lease commitments totaled $97.6 million, including $52.1 million due after five years. Total assets were $430.8 million and stockholders’ equity was $289.2 million.
- Accumulated deficit was $395.9 million. Unrealized losses on marketable securities were $3.4 million for the year; the filing reported no credit-loss allowance on those securities.
Material changes and business developments
- Collaboration revenue fell $14.7 million year over year, mainly reflecting lower Roche revenue after the BRAF target collaboration ended and lower Calico revenue; increased Biogen revenue partly offset the decline.
- R&D expense increased $23.2 million, driven chiefly by clinical program staffing, clinical-trial activity, and expanded facilities. G&A expense rose $9.5 million, primarily from personnel and facilities.
- Operating cash use increased $19.0 million. Investing activities provided $58.4 million in 2022, mainly from net maturities of marketable securities; financing activities provided $1.1 million. The 2021 financing comparison included $169.5 million of net proceeds from a follow-on offering.
- The company initiated CFT8634’s Phase 1/2 trial in May 2022. It initiated CFT1946’s trial in January 2023, after year-end. CFT8919 completed IND-enabling activities in December 2022. CFT7455 remained in dose escalation; its regimen was modified after dose-limiting neutropenia.
- The company added Watertown office and laboratory space under a lease amendment and subleased part of its premises through June 2025.
Outlook, risks, and unusual items
- Management estimated that year-end funds, together with expected future collaboration payments, would fund the existing operating plan through the end of 2024. The filing cautions that this estimate depends on assumptions and that funds will not carry candidates through regulatory approval; substantial additional financing will be needed. The financial statements also state that funds were expected to cover at least 12 months from issuance.
- Management expects continued significant operating losses and increased R&D spending. No product revenue is expected for the foreseeable future; profitability is uncertain.
- Key clinical risk includes neutropenia with CFT7455, which required a dosing-schedule change. All programs remain investigational, and early clinical or preclinical findings may not predict later efficacy or safety.
- Calico’s extended research term was due to end in March 2023 and Biogen’s in June 2023. Future partner payments, milestones, and royalties are uncertain and depend on research progress and partner decisions.
- Manufacturing depends on third-party suppliers, with no redundant supply source in place for drug substance or drug product. The company also relies on CROs for clinical trials.
- Debt covenants and collateral requirements constrain flexibility; the loan requires a minimum $3.0 million cash balance in controlled accounts. The company reported no material legal proceedings, and management concluded disclosure controls and internal control over financial reporting were effective as of year-end.
- Management identified possible expedited development pathways as contingent on future clinical results and regulatory discussions; no approval or specific development timeline was assured.
Important facts for investors to verify
- Latest enrollment, safety, dose selection, and efficacy data for CFT7455, CFT8634, and CFT1946, including whether CFT7455’s revised schedule addresses neutropenia.
- Current cash runway against actual spending, collaboration receipts, and financing needs; reconcile the end-of-2024 operating-plan estimate with subsequent results and guidance.
- Debt repayment status, variable-rate exposure, covenant compliance, and the June 2024 maturity.
- Status and economics of Roche, Biogen, and Calico programs as their research terms expire, including any exercised options, milestones, or program terminations.
- Clinical-trial timelines, manufacturing capacity and backup suppliers, and any changes to the company’s pipeline or development priorities.